Benzinga · Aug 25, 2026
FDA Approves Drug To Treat HIV Infection in Newborns
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns
NASDAQ · PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$29.02
Up+$0.47 (+1.65%)
Updated Sep 3, 2026, 6:35 AM
SID Score
7.3/10
Composite research score
Smart Money
74/100
Bullish
- Market cap
- 146.75B
- P/E ratio
- 14.94
- Dividend yield
- 5.93%
- 52-week range
- $23.62 – $29.09
- Volume
- 39.28M
- Avg. volume
- 68.83M
Price performance
PFE price history
1M range · 21 trading sessions · Daily adjusted prices
PFE closed at $29.02 after 21 trading sessions, up 12.44% for the selected period.
- Last close
- $29.02
- Period change
- +12.44%
- Period low
- $25.81
- Period high
- $29.02
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $28.79 | $29.09 | $28.705 | $29.02 | 39.28M |
| Sep 1, 2026 | $28.818 | $29.09 | $28.465 | $28.55 | 42.49M |
| Aug 31, 2026 | $27.85 | $28.70 | $27.64 | $28.46 | 45.93M |
| Aug 28, 2026 | $28.00 | $28.02 | $27.77 | $27.96 | 27.18M |
| Aug 27, 2026 | $27.97 | $28.18 | $27.83 | $28.02 | 31.17M |
| Aug 26, 2026 | $28.44 | $28.50 | $28.145 | $28.30 | 35.07M |
| Aug 25, 2026 | $27.915 | $28.58 | $27.84 | $28.57 | 31.92M |
| Aug 24, 2026 | $28.10 | $28.1561 | $27.81 | $27.97 | 23.85M |
| Aug 21, 2026 | $27.77 | $28.425 | $27.655 | $28.07 | 37.11M |
| Aug 20, 2026 | $28.00 | $28.16 | $27.645 | $27.79 | 29.3M |
| Aug 19, 2026 | $27.60 | $28.435 | $27.58 | $28.24 | 59.8M |
| Aug 18, 2026 | $27.15 | $27.395 | $27.10 | $27.25 | 34.66M |
| Aug 17, 2026 | $26.76 | $27.02 | $26.55 | $26.87 | 29.26M |
| Aug 14, 2026 | $26.66 | $26.915 | $26.42 | $26.79 | 23.17M |
| Aug 13, 2026 | $26.49 | $26.95 | $26.41 | $26.80 | 35.36M |
| Aug 12, 2026 | $26.385 | $26.435 | $26.18 | $26.31 | 32.59M |
| Aug 11, 2026 | $26.94 | $27.20 | $26.47 | $26.62 | 37.94M |
| Aug 10, 2026 | $26.585 | $27.19 | $26.52 | $27.05 | 49.79M |
| Aug 7, 2026 | $26.22 | $26.76 | $26.0503 | $26.76 | 42.74M |
| Aug 6, 2026 | $26.01 | $26.20 | $25.81 | $26.20 | 51.07M |
| Aug 5, 2026 | $25.50 | $25.81 | $25.30 | $25.81 | 47.06M |
Latest PFE news
The latest Smart Investors Daily articles mentioning PFE.
Stock researchCompany · Overview
PFE research
Overview
Company profile and research snapshot.
Company profile
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $30.00
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | Guggenheim | Buy | — |
| Jul 13, 2026 | BMO Capital | Outperform | — |
| Jul 10, 2026 | B of A Securities | Neutral | — |
| Jul 8, 2026 | JP Morgan | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 22, 2026
Prediction: This Is Where Pfizer Stock Will Be in 2030
Pfizer is facing material patent expirations over the next two years, but that will be over by 2030.
Yahoo · Aug 21, 2026
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Yahoo · Aug 21, 2026
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
